Diana Machado

TL;DR: In this article, the authors described the mode of action of the 2-phenylquinoline efflux inhibitor (4-(piperazin-1-yl)ethoxy)-2-(4-propoxyphenyl) quinolone -PQQ4R against Escherichia coli, by studding its efflux inhibitory ability, its synergistic activity in combination with antibiotics, and compared its effects with the inhibitors phenyl-arginine-β-naphthylamide (PAβN) and chlorpromazine (CPZ).

TL;DR: In this paper, the role of efflux in colistin-heteroresistant populations of Acinetobacter baumannii clinical isolate was investigated by synergistic assays with efflux inhibitors, real-time efflux activity measurements and analysis of the mRNA transcriptional levels of selected efflux pump genes.

TL;DR: Using a classical molecular simplification approach, a series of 36 quinolines were synthesized and evaluated as in Vitro inhibitors of Mycobacterium tuberculosis growth, indicating that this class of compounds may furnish candidates for the future development of antituberculosis drugs.

TL;DR: Analysis of the distribution of the mutations found by genetic clustering showed that in the Q1 cluster, two mutations were enough to ensure development of XDR-TB from an MDR strain, revealing that eis G-10A mutations may result in amikacin resistance undetectable by widely used phenotypic assays.

TL;DR: A screening of more than 1,500 drug-resistant strains of Mycobacterium tuberculosis revealed evolutionary patterns characteristic of positive selection for three alanine racemase (Alr) mutations, which demonstrated that these mutations likely confer resistance to d-cycloserine.